文献速递其他结缔组织病

单核细胞Siglec-1表达与幼年皮肌炎干扰素特征相关并可预测治疗反应

Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究在21例新诊断幼年皮肌炎(JDM)患者中检测单核细胞Siglec-1表达,发现其与临床疾病活动度相关,高表达者3个月内需强化治疗的风险更高(55% vs 0%,P=0.01),且预测治疗反应的AUC优于IFN评分(0.87 vs 0.53,P=0.01)。

要点

  • JDM患者单核细胞Siglec-1表达及IFN评分均升高,且与临床疾病活动度相关。
  • 诊断时高Siglec-1表达者3个月内需强化治疗比例更高(55% vs 0%,P=0.01)。
  • Siglec-1预测治疗反应优于IFN评分(AUC 0.87 vs 0.53,P=0.01)。

核心结论

  • 单核细胞Siglec-1是JDM中新型IFN诱导生物标志物,与临床疾病活动度相关并可识别治疗反应欠佳风险患者。

研究设计与样本

  • 研究纳入21例新诊断JDM患者,治疗前用流式细胞术检测循环单核细胞Siglec-1,其中10例在随访中亦检测。
  • 用RT-qPCR检测5个I型IFN刺激基因(MX1、IFI44、IFI44L、LY6E、IFIT3)以确定IFN特征并计算IFN评分。
  • 用多重免疫分析检测IFN诱导血浆蛋白CXCL10和galectin-9。

主要发现

  • JDM患者Siglec-1和IFN评分较对照组升高,且与临床疾病活动度相关。
  • 按诊断时Siglec-1表达分层,高表达者诊断后3个月内需强化治疗的风险更高(55% vs 0%,P=0.01)。
  • Siglec-1与血浆CXCL10(rs=0.81,P<0.0001)和galectin-9(rs=0.83,P<0.0001)强相关。
  • Siglec-1预测治疗反应优于IFN评分(AUC 0.87 vs 0.53,P=0.01)。

关键数值与推荐

  • 高Siglec-1表达者3个月内需强化治疗比例为55%,低表达者为0%(P=0.01)。
  • Siglec-1与CXCL10相关系数rs=0.81(P<0.0001),与galectin-9相关系数rs=0.83(P<0.0001)。
  • Siglec-1预测治疗反应AUC为0.87,IFN评分为0.53(P=0.01)。

临床怎么用

  • JDM诊断时可检测单核细胞Siglec-1表达以辅助评估疾病活动度和预测治疗反应欠佳风险。
  • 高Siglec-1表达患者可能需要更密切监测和早期治疗强化。

局限性

  • 样本量小(21例新诊断患者,仅10例有随访数据),需进一步研究验证这些发现及其临床潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: JDM is a rare chronic immune-mediated inflammatory disease with a predominant role for type I IFN responses. We aimed to determine the potential of Siglec-1 expression on monocytes as a novel IFN-inducible biomarker for disease activity monitoring and prediction of treatment response in patients with JDM. METHODS: Siglec-1 was measured by flow cytometry on circulating monocytes of 21 newly diagnosed JDM patients before start of treatment and, for 10 of these, also during follow-up. The expression levels of five type I IFN-stimulated genes, MX1, IFI44, IFI44L, LY6E and IFIT3, were measured by RT-qPCR to determine the IFN signature and calculate an IFN score. IFN-inducible plasma proteins CXCL10 and galectin-9 were measured by multiplex immunoassay. RESULTS: Siglec-1 and IFN score were increased in JDM patients compared with controls and correlated with clinical disease activity. Stratification of patients by Siglec-1 expression at diagnosis identified those with high Siglec-1 expression as having a higher risk of requiring treatment intensification within the first 3 months after diagnosis (55% vs 0% of patients, P = 0.01). Siglec-1 expression strongly correlated with plasma levels of previously validated biomarkers CXCL10 (rs = 0.81, P < 0.0001) and galectin-9 (rs = 0.83, P < 0.0001), and was superior to the IFN score in predicting treatment response (area under the curve 0.87 vs 0.53, P = 0.01). CONCLUSION: Siglec-1 on monocytes is a novel IFN-inducible biomarker in JDM that correlates with clinical disease activity and identifies patients at risk for a suboptimal treatment response. Further studies are required to validate these findings and their clinical potential.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lerkvaleekul B, Veldkamp SR, van der Wal MM, et al. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology (Oxford). 2022. PMID: 34387304. doi:10.1093/rheumatology/keab601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。